Download MendeleyProperty-Biased Covalent DNA-Encoded Library Screening Enabled the Discovery of AM-8719, A Structurally Novel, CNS-Penetrant KRAS G12C Inhibitor.
Rast, S., Morgan-Fisher, M., Blomquist, S.D., Cadahia, J.P., Cowland, S., Franch, T., Glibstrup, E., Gouliaev, A., Haahr Hansen, M., Kontijevskis, A., Kronborg, T., Moretti, L., Nadali, A., Nielsen, S., Leth-Petersen, S., Rabe, M., Alafate, A., Allen, J.R., Banerjee, A., Booker, S.K., Butler, J.R., Hot, I., Huang, D., Kaller, M.R., Kapoor, R., Liu, Q., Lopez, P., Ma, V., Manoni, F., Medina, J.M., Pickrell, A.J., Wang, H.L., Xie, J., Zhang, W., Mohr, C., Chen, K., Saiki, A.Y., Wang, P., Leavitt, M., Rex, K., Zhong, G., Zou, L., Lade, J., Dahal, U.P., Farhan, N., Agarwal, P., Zandkarimi, B., Zhu, K., Husemoen, G., Tamayo, N.A., Lanman, B.A.(2026) J Med Chem 69: 19050-19064
- PubMed: 42593915 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1021/acs.jmedchem.6c01357
- Primary Citation Related Structures:
12KZ, 12LA, 12LB, 12LC - PubMed Abstract:
Activating mutations in the Kirsten rat sarcoma (KRAS) gene are prevalent oncogenic drivers in nonsmall cell lung cancer (NSCLC). Patients harboring KRAS-mutant lung cancers frequently develop central nervous system (CNS) metastases. Although approved KRAS G12C inhibitors (i.e., sotorasib and adagrasib) show promising clinical CNS activity, these agents demonstrate low preclinical brain-to-plasma ratios, raising the question of whether compounds with elevated preclinical Kp,uu,brain values might show enhanced clinical performance. Here, we report the first successful application of DNA-encoded library (DEL) screening technology to the identification of CNS-penetrant covalent inhibitors of KRAS G12C. In this effort, a property-biased covalent DEL-screening approach enabled the discovery of a structurally novel series of hydrogen bond donor-free KRAS G12C inhibitors with improved CNS exposure. Leveraging structure-based design, we refined this hit series to deliver lead compound AM-8719, a CNS-penetrant, orally efficacious KRAS G12C inhibitor exhibiting 200-fold improved potency with respect to initial screening hits.
- Amgen Research, Rønnegade 8, Copenhagen2100, Denmark.
Organizational Affiliation:
